Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (NCT05222555)
A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, multicentre study too Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) who have had at least one, but no more than three prior systemic regimens and who are not eligible for high dose chemotherapy (HDC) with autologous stem-cell transplantation (ASCT) at the time of study entry.
Who can join: Review the eligibility criteria below.
Location: Morristown Memorial Hospital — Morristown, New Jersey
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (62 Sites)
Showing the first 25 of 62 sites.
- Morristown Memorial Hospital — Morristown, New Jersey
- Texas Oncology-Baylor Charles A. Sammons Cancer Center - USOR — Dallas, Texas
- Vista Oncology — Olympia, Washington
- UK St. Pölten — Sankt Pölten, Lower Austria
- Klinikum Wels Grieskirchen — Wels, Upper Austria
- Universitatsklinikum Salzburg — Salzburg,
- Fakultni nemocnice Brno — Brno,
- Fakultni nemocnice Ostrava — Ostrava,
- Fakultni nemocnice Kralovske Vinohrady — Prague,
- Vseobecna Fakultni Nemocnice V Praze — Prague,
- Fakultni nemocnice v Motole — Prague,
- Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon — Grenoble, Isère
- CHU Nantes — Nantes, Loire-Atlantique
- Centre Hospitalier Le Mans — Le Mans, Sarthe
- CHU de Poitiers — Poitiers, Vienne
- Soroka University Medical Centre — Beersheba, Southern District
- Shamir Medical Center Assaf Harofeh — Be’er Ya‘aqov,
- Lady Davis Carmel Medical Center — Haifa,
- Hadassah Medical Center - Hadassah Ein Kerem — Jerusalem,
- ZIV Medical Center — Safed,
- Ospedale Santa Maria Delle Croci — Ravenna, Emilia-Romagna
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico — Milan, Lombardy
- ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda — Milan, Lombardy
- Fondazione IRCCS Policlinico San Matteo di Pavia — Pavia, Lombardy
- ASST di Monza - Azienda Ospedaliera San Gerardo — Monza, Monza E Brianza
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diffuse Large B Cell Lymphoma
- Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia — Honolulu, Hawaii
- Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma — Boston, Massachusetts
- Copanlisib Plus Venetoclax in R/R DLBCL — Duarte, California
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers — Basking Ridge, New Jersey
- Split-Dose R-CHOP for Older Adults With DLBCL — Madison, Wisconsin
Explore by condition: All Diffuse Large B Cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.